Search

Your search keyword '"Kilbride, Sally"' showing total 60 results
Start Over Author "Kilbride, Sally"
60 results on '"Kilbride, Sally"'

51. Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT

Author

Dransfield, Mark, primary, Crim, Courtney, additional, Criner, Gerard, additional, Halpin, David, additional, Han, Meilan, additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lipson, David, additional, Lomas, David, additional, Martinez, Fernando, additional, Singh, David, additional, and Wise, Robert, additional

Published
2018
Full Text
View/download PDF

52. Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening

Author

Singh, Dave, primary, Criner, Gerard, additional, Day, Nicola C., additional, Dransfield, Mark, additional, Halpin, David M.G., additional, Han, Meilan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lipson, David A, additional, Lomas, David A., additional, Pascoe, Steve, additional, Tabberer, Maggie, additional, Wise, Robert, additional, and Martinez, Fernando J., additional

Published
2018
Full Text
View/download PDF

54. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

Author

Lipson, David A., primary, Barnhart, Frank, additional, Brealey, Noushin, additional, Brooks, Jean, additional, Criner, Gerard J., additional, Day, Nicola C., additional, Dransfield, Mark T., additional, Halpin, David M.G., additional, Han, MeiLan K., additional, Jones, C. Elaine, additional, Kilbride, Sally, additional, Lange, Peter, additional, Lomas, David A., additional, Martinez, Fernando J., additional, Singh, Dave, additional, Tabberer, Maggie, additional, Wise, Robert A., additional, and Pascoe, Steven J., additional

Published
2018
Full Text
View/download PDF

55. Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction

Author

Martinez, Fernando J., primary, Vestbo, Jørgen, additional, Anderson, Julie A., additional, Brook, Robert D., additional, Celli, Bartolome R., additional, Cowans, Nicholas J., additional, Crim, Courtney, additional, Dransfield, Mark, additional, Kilbride, Sally, additional, Yates, Julie, additional, Newby, David E., additional, Niewoehner, Dennis, additional, and Calverley, Peter M. A., additional

Published
2017
Full Text
View/download PDF

56. HIGH-SENSITIVITY CARDIAC TROPONIN I AND RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH COPD AND HEIGHTENED CARDIOVASCULAR RISK: A BIOMARKER SUB-STUDY OF THE SUMMIT TRIAL

Author

Mills, Nicholas L., primary, Anderson, Julie A., additional, Brook, Robert D., additional, Calverley, Peter M.A., additional, Celli, Bartolome R., additional, Cowans, Nicholas J., additional, Crim, Courtney, additional, Dixon, Ian J., additional, Kilbride, Sally, additional, Martinez, Fernando, additional, Vestbo, Jørgen, additional, Yates, Julie, additional, and Newby, David E., additional

Published
2017
Full Text
View/download PDF

58. Pulse wave velocity (PWV) in patients (pts) with moderate COPD and cardiovascular risk: The effect of an inhaled long-acting β2-agonist/corticosteroid (SUMMIT)

Author

Crim, Courtney, primary, Brook, Robert, additional, Anderson, Julie, additional, Kilbride, Sally, additional, Calverley, Peter, additional, Celli, Bartolome, additional, Martinez, Fernando, additional, Vestbo, Jørgen, additional, Yates, Julie, additional, and Newby, David, additional

Published
2016
Full Text
View/download PDF

60. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

Author

Celli, Bartoleme, Crater, Glenn, Kilbride, Sally, Mehta, Rashmi, Tabberer, Maggie, Kalberg, Chris, Church, Alison, Celli, Bartolome, and Kalberg, Chris J

Abstract

Background: Combination long-acting bronchodilator therapy may be more effective than long-acting bronchodilator monotherapy in chronic obstructive pulmonary disease (COPD).Objectives: To compare the efficacy and safety of once-daily umeclidinium/vilanterol (UMEC/VI) 125/25 mcg with placebo and UMEC or VI monotherapy in COPD.Methods: This was a double-blind, placebo-controlled, parallel-group study. A total of 1493 patients were randomized (3:3:3:2) to 24 weeks of treatment with UMEC/VI 125/25 mcg, UMEC 125 mcg, VI 25 mcg, or placebo once-daily via dry powder inhaler.Results: Primary efficacy endpoint was trough forced expiratory volume in one second (FEV1) on Day 169 (23-24 h post-dose). Additional lung-function, symptomatic and health-related quality of life endpoints were also assessed. Safety evaluations included: adverse events, vital signs, electrocardiography and clinical laboratory measurements. All active treatments significantly improved trough FEV1 vs placebo (0.124-0.238 L, all p<0.001). Improvements with UMEC/VI 125/25 mcg were significantly greater than for UMEC 125 mcg or VI 25 mcg (0.079 L and 0.114 L; both p≤0.001). Improvements for UMEC/VI 125/25 mcg vs placebo were observed for the transition dyspnea index (1.0 unit; p<0.001), rescue albuterol use at Weeks 1-24 (-1.5 puffs/day) and St. George's Respiratory Questionnaire (-3.60 units, p<0.001). No safety signals were observed.Conclusions: Once-daily UMEC/VI 125/25 mcg was well tolerated and provided greater improvements in lung function, health status, and dyspnea scores compared with monotherapy components and placebo over 24 weeks. This study supports the use of UMEC/VI 125/25 mcg for the maintenance treatment of COPD.Clinical Trial Registration: protocol number: DB2113361; ClinicalTrials.gov identifier: NCT01313637. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results